Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering
Rhea-AI Summary
Bausch Health (NYSE:BHC) and its dermatology unit Ortho Dermatologics launched Biafine® Skin Recovery Emulsion for U.S. consumers via select online channels on April 14, 2026. First developed in France in 1971, Biafine is a lightweight, clinically supported emulsion for dry, sensitive, or stressed skin.
The product is available directly to patients through select online retailers including Amazon, and dermatology practices can supply it via the Ortho Dermatologics Direct platform when recommended by a clinician.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – BHC
On the day this news was published, BHC declined 0.70%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BHC gained 2.14% while several peers like ALVO, HCM, INDV, and AMRX also rose, but no peers appeared in the momentum scanner and SUPN declined, pointing to stock-specific rather than broad sector momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Earnings date notice | Neutral | +7.4% | Set date and call details for Q1 2026 financial results release. |
| Mar 26 | Scholarship program | Positive | +0.8% | Announced 2026 ASPIRE HIGHER scholarships for students with dermatologic conditions. |
| Feb 23 | Aesthetic device launch | Positive | -2.5% | Launched Clear + Brilliant Touch laser in Canada after Health Canada approval. |
| Feb 19 | Product milestone | Positive | -4.2% | Marked 25 years of ARESTIN with note of expanded commercial presence. |
| Feb 18 | Earnings results | Positive | -4.2% | Reported Q4 and full-year 2025 revenue and EBITDA growth with 2026 guidance. |
Recent history shows multiple positive operational or earnings updates followed by negative price reactions, suggesting a tendency for the stock to sell off or lag on good news.
Over the last few months, Bausch Health reported solid Q4 2025 and full-year 2025 growth, with revenues of $2.80B in Q4 and $10.27B for the year, plus higher adjusted EBITDA, yet the stock declined 4.2% on that release. Product and franchise milestones in aesthetics (Clear + Brilliant Touch in Canada) and dental (25 years of ARESTIN and recent expansion) also saw negative next-day moves. By contrast, an earnings-date announcement on Mar 31, 2026 produced a 7.36% gain, and a scholarship program update had a small positive reaction, highlighting mixed responses to news.
Market Pulse Summary
This announcement highlights broader U.S. access to Biafine®, a long‑standing French skin recovery emulsion, via select online channels including Amazon, with additional distribution through the Ortho Dermatologics Direct platform for practices. The move adds another branded asset to Bausch Health’s dermatology portfolio alongside other recent aesthetics and dental milestones. Investors may watch how digital availability supports dermatology engagement, how it complements existing product lines, and how upcoming events like the Q1 2026 results update shape the broader growth narrative.
Key Terms
emulsion medical
dermatology medical
dermatologists medical
AI-generated analysis. Not financial advice.
The skin recovery emulsion for dry, sensitive, or stressed skin is now available through select online channels
First developed in
Tom Stern, Vice President and General Manager of the Ortho Dermatologics business reflected, "We are proud to offer dermatology practices and patients access to a formula that has earned the trust of both professionals and consumers for decades."
Biafine is available directly to patients through select online channels, including Amazon. Dermatology practices can provide the product through the Ortho Dermatologics Direct platform which supports in-office access when a dermatologist recommends it as part of a skincare regimen.
For more information about Biafine, please visit www.biafine.com.
About Biafine®
Biafine® is a French-developed skincare emulsion introduced in 1971, designed to support the skin's natural barrier function while maintaining hydration and comfort. For decades, the formula has been recognized by dermatologists and consumers for its unique texture and versatility in skincare routines. Biafine is offered in
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our dermatology business, Ortho Dermatologics is one of the largest prescription and aesthetic dermatology businesses dedicated to helping patients in the treatment of a range of conditions, including psoriasis, onychomycosis, actinic keratosis, acne, atopic dermatitis and other dermatoses. More information can be found at https://www.ortho-dermatologics.com and connect with us on LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
Biafine is a registered trademark of Ortho Dermatologics or its affiliates. | |
Investor Contact: | Media Contact: |
Garen Sarafian | Katie Savastano |
877-281-6642 (toll-free) | (908) 569-3692 |
BHC-PRODUCT | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-healths-dermatology-business-ortho-dermatologics-announces-the-launch-of-biafine-an-iconic-french-skincare-product-through-convenient-online-ordering-302739556.html
SOURCE Bausch Health Companies Inc.